Evaluation of Cemiplimab in Combination With Platinum-Doublet Chemotherapy in First-Line (1L) Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) in Adult United States (US) Patients

Conditions: Advanced Non-small Cell Lung Cancer Interventions: Drug: REGN2810; Other: Platinum-doublet chemotherapy Sponsors: Regeneron Pharmaceuticals Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials